Displaying drugs 7276 - 7300 of 8495 in total
Sabatolimab
Sabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).).
Investigational
Matched Description: … Sabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With …
INM004
INM004, a Neutralizing Equine Anti-Stx Hyperimmune Immunoglobulin F(Ab')2 Fragment, is currently being investigated to treat Shiga-toxin producing bacterial infection relating to the prevention of hemolytic uremic syndrome.
Investigational
Matched Description: … currently being investigated to treat Shiga-toxin producing bacterial infection relating to the prevention of …
FB-101
FB-101 is a c-Abl inhibitor. Developed by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).
Experimental
Investigational
Matched Description: … Developed by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders …
AMG-553
AMG-553 is an adoptive, anti-FLT3 chimeric antigen receptor T-cell therapy generated through transduction of autologous T-cells with a self-inactivating human immunodeficiency virus-1 based lentiviral vector.
Investigational
Matched Description: … 553 is an adoptive, anti-FLT3 chimeric antigen receptor T-cell therapy generated through transduction of …
Ichorcumab
Ichorcumab is under investigation in clinical trial NCT03251482 (A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery).
Investigational
Matched Description: … Ichorcumab is under investigation in clinical trial NCT03251482 (A Study to Evaluate the Safety and Efficacy of …
Pemrametostat
Pemrametostat is under investigation in clinical trial NCT03614728 (Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)).
Investigational
Matched Description: … investigation in clinical trial NCT03614728 (Study to Investigate the Safety and Clinical Activity of …
CDX-301
CDX-301 is under investigation in clinical trial NCT02129075 (A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma).
Investigational
Matched Description: … trial NCT02129075 (A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of …
Azelaprag
Azelaprag is under investigation in clinical trial NCT06515418 (Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared With Tirzepatide Alone in Participants With Obesity Aged 55 Years and Over).
Investigational
Matched Description: … Azelaprag is under investigation in clinical trial NCT06515418 (Efficacy and Safety of Oral Azelaprag …
Piclamilast
Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. The structure for piclamilast was first elucidated in a 1995 European patent...
Experimental
Matched Description: … It has been investigated for its applications to the treatment of conditions such as chronic obstructive ... first elucidated in a 1995 European patent application and exhibits the structural functionalities of …
Rindopepimut
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted...
Investigational
Matched Description: … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated ... injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of …
Velafermin
Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated activity in multiple animal models. Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the...
Investigational
Matched Description: … by fostering the regeneration and repair of the cells lining the gastrointestinal tract. ... Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis …
Valopicitabine
The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus (HCV) activity. Upon administration, valopicitabine is converted into 2'-C-methylcytidine; upon phosphorylation into its 5-triphosphate form, this metabolite inhibits viral RNA chain elongation and viral RNA-dependent RNA polymerase activity. This blocks viral production of HCV RNA and thus...
Experimental
Matched Description: … This blocks viral production of HCV RNA and thus viral replication. [from NCI] ... The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus …
Erythroxylum catuaba bark
"Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the Erythroxylum genus, though this name is also applied to infusions of plants belonging to other genera. The infusion is thought to carry stimulant and aphrodisiac effects, and catuaba made specifically with Trichilia...
Experimental
Matched Description: … "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _ ... Erythroxylum_ genus, though this name is also applied to infusions of plants belonging to other genera …
CVnCoV Vaccine
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … Phase 1 clinical trials of this vaccine (NCT04449276). ... As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence …
Tetraethylammonium
Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. As an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide....
Experimental
Investigational
Matched Description: … The most common use of tetraethylammonium presently is as a pharmacological research agent that blocks ... Its mechanism of action is still being investigated, but it is known that tetraethylammonium blocks autonomic ... Because of its inhibitory actions at the autonomic ganglia, tetraethylammonium was thought to be a potential …
Corticosterone
An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
Experimental
Matched Description: … (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437) …
Pumactant
Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).
Investigational
Matched Description: … It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC …
Filanesib
Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
Investigational
Matched Description: … potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of …
Patritumab
Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
Investigational
Matched Description: … Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by …
Apricoxib
Apricoxib has been used in trials studying the treatment and prevention of Lung Cancer, Breast Cancer, Pancreatic Cancer, Non Small Cell Lung Cancer, and Metastatic Pancreatic Cancer, among others.
Investigational
Matched Description: … Apricoxib has been used in trials studying the treatment and prevention of Lung Cancer, Breast Cancer …
Dipropyl-4-hydroxytryptamine
Dipropyl-4-hydroxytryptamine is the 4-hydroxyl analog of dipropyltryptamine (DPT). Dipropyl-4-hydroxytryptamine was first synthesized by Alexander Shulgin. This agent and its properties haven't been fully elucidated.
Experimental
Matched Description: … Dipropyl-4-hydroxytryptamine is the 4-hydroxyl analog of dipropyltryptamine (DPT). …
AZD-9977
AZD-9977 is under investigation in clinical trial NCT03843060 (A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers).
Investigational
Matched Description: … is under investigation in clinical trial NCT03843060 (A Phase 1 Study to Assess the Pharmacokinetics of …
AGG-523
AGG-523 is under investigation in clinical trial NCT00380900 (Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy subjects and in subjects with osteoarthritis).
Investigational
Matched Description: … trial NCT00380900 (Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of …
Glumetinib
Glumetinib is under investigation in clinical trial NCT04270591 (Assess the Anti-tumor Activity and Safety of Glumetinib in Patient With Advanced C-met-positive Non-small Cell Lung Cancer).
Investigational
Matched Description: … Glumetinib is under investigation in clinical trial NCT04270591 (Assess the Anti-tumor Activity and Safety of …
LX-7101
LX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).
Investigational
Matched Description: … investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of …
Displaying drugs 7276 - 7300 of 8495 in total